SEC Form 4 · accession 0001290976-26-000004
Evommune, Inc. · EVMN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur S Kirsch
Director
Period of report
Jul 7, 2026
Accepted (ET)
Jul 8, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002044725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 7, 2026 | P | 10,000 | $13.30 | A | 10,000 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.